Eledon Pharmaceuticals, Inc.: BIOTECHNOLOGY VALUE FUND L P amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Biotechnology Value Fund L.P. filed an amended Schedule 13G with the SEC (accession 0000921895-26-003175) updating its beneficial ownership stake in Eledon Pharmaceuticals, Inc. The filing signals a change in the fund's position, though the amended disclosure did not specify the revised share count or percentage in the headline. The update matters because 13G amendments can reflect shifts in passive or institutional ownership that influence liquidity and shareholder composition in a small-cap biotech. Investors will watch for the full filing details to confirm whether the fund increased, trimmed, or maintained its stake.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Eledon Pharmaceuticals, Inc., Biotechnology Value Fund L.P.